MUC1 and breast cancer: The expansion, persistence, potent anti-tumor activity, and safety profile exhibited by the second generation CAR.MUC1 and 4/7ICR modified T cells (2G.4/7ICR) support the clinical translation of this approach for the treatment of patients with breast cancer.